Trial Profile
A Randomized, Double-Blind, Parallel Group 24 Week Placebo-Controlled Efficacy and Safety Study with a 28 Week Long Term Extension, of Nebulized Fluticasone Propionate (FP) /Formoterol Fumarate (FF) Combination Compared with FP and FF Monotherapy in Patients with COPD
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2015
Price :
$35
*
At a glance
- Drugs Formoterol/fluticasone propionate (Primary) ; Fluticasone propionate; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Mylan Specialty
- 28 Feb 2015 Status changed from recruiting to discontinued as per European Clinical Trials Database record.
- 21 Oct 2014 New trial record